FDA Determines Regulatory Review Period for AXUMIN Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially approved the regulatory review period for AXUMIN, a human drug product, in accordance with patent extension regulations, following a submission to the U.S. Patent and Trademark Office (USPTO).